BDSX
High convictionBiodesix, Inc.
Healthcare · NASDAQ
$190.0M mkt cap
Brief updated Jun 28, 2026
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinic
Biodesix rides risk-off rotation into defensive healthcare, but catastrophic financials demand scrutiny before conviction holds.
Biodesix provides blood-based lung cancer diagnostic tests, a niche with genuine clinical utility and an analyst consensus buy rating. The macro environment is actively rotating toward defensive healthcare names, a dynamic the composite conviction score of 72 out of 100 treats as a direct tailwind worth 20 points alone. The financial reality is brutal: revenue growth is deeply negative, net margins are negative 3326 percent, and the DCF model produces a negative intrinsic value of $279 per share. The tension is sharp — the macro narrative and analyst consensus point one direction, while every fundamental number points the other.
Why now
The active risk-off rotation into defensive sectors is live, not anticipated, giving diagnostic healthcare names like Biodesix a near-term bid that is macro-driven rather than earnings-driven. A potential Federal Reserve rate hike as soon as late July, flagged by a JPMorgan executive, would tighten financial conditions and compress the speculative premium that keeps a deeply unprofitable diagnostics company trading above zero.
Key risks
The negative DCF intrinsic value is not a rounding error — it reflects a business where costs are structurally overwhelming revenue, and gross margin data showing 8208 percent is almost certainly a data anomaly that masks true unit economics. A rate hike in the next six weeks would hit speculative small-cap healthcare names disproportionately hard, directly contradicting the macro tailwind thesis. Execution risk is existential: if Nodify test volume does not inflect materially upward in the next two quarters, cash runway becomes the dominant story.
What to watch
Watch sequential test volume growth for Nodify XL2 and Nodify CDT in the next earnings report — any positive inflection in volumes is the single most important confirmation signal. Also watch whether the company provides updated cash runway guidance; a runway shorter than six quarters would override the macro tailwind entirely.
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid US Attacks on Iran
The US has launched attacks on Iran, leading to increased geopolitical tensions and a rise in risk-off sentiment, with exchange-traded funds and equity futures higher pre-bell on Thursday as investors seek safe-haven assets.
Jun 15, 2026
Circle Your Calendars for July 29. JPMorgan Executive Says Fed Chair Kevin Warsh Could Raise Rates in As Little as Six Weeks.
JPMorgan executive suggests Fed Chair Kevin Warsh may raise interest rates as early as six weeks from July 29, indicating a potential shift in monetary policy. This could impact market expectations and asset prices.
Jun 22, 2026
Gold Extends Losses as Fed Rate-Hike Outlook Supports Dollar
The Federal Reserve's outlook on interest rate hikes has strengthened, supporting the US dollar and leading to extended losses in gold prices. This development may impact investor risk appetite and currency markets.
Jun 22, 2026
Chart of the Day 6-19-26- In Warsh's Wake, Hike Odds Spike
The odds of a interest rate hike have increased following comments from a key central bank official, indicating a potential shift in monetary policy. This change in guidance could impact market expectations and asset prices.
Jun 22, 2026
Earnings surprises
+35.7%
2026-05
+53.3%
2026-02
+27.5%
2025-11
-14.3%
2025-08
—
2025-05
TSMC stock drops 4.1% amid a $2 trillion AI rout, indicating a potential shift in investor sentiment towards AI-related stocks and the broader tech sector. This event may have implications for the tech industry and the global economy.
The US equity indexes are sliding ahead of Fed Governor Warsh's press briefing and big-tech results, as President Trump vows to hit Iran hard, escalating geopolitical tensions. This escalation could lead to increased market volatility and risk aversion.
The equities market is experiencing intraday losses ahead of the highly anticipated Federal Reserve decision, which could significantly impact market direction and investor sentiment. The decision, coupled with major tech earnings reports, is poised to influence the overall economic outlook.
TSMC's Japan semiconductor fabrication plant is gradually resuming operations following an earthquake-induced disruption. This matters because TSMC is a critical node in the global semiconductor supply chain, and even partial outages can ripple through electronics and chip-dependent industries.
US Strategic Petroleum Reserve levels have fallen to a 43-year low, reducing the government's capacity to buffer oil price shocks at a time of active Middle East conflict. This structural vulnerability in US energy policy raises concerns about energy security and the ability to respond to supply disruptions.
Generated Sun, 28 Jun 2026 06:12:32 GMT by Decifer intelligence engine. For informational purposes only — not investment advice. Decifer Intelligence Hub.